The Effects of Phosphomimetic Lid Mutation on the Thermostability of the N-terminal Domain of MDM2

Journal of Molecular Biology

Volumn 398, Issue 3, 2010, Pages 414-428

  Worrall, Erin G ^a   Worrall, Liam ^b,c   Blackburn, Elizabeth ^b   Walkinshaw, Malcolm ^b   Hupp, Ted R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Institute of Translational and Chemical Biology   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Ligand; MDM2; Nutlin 3; P53; Phosphorylation

Indexed keywords

LIGAND; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; GENE DELETION; GENE MUTATION; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; THERMOSTABILITY; WILD TYPE; AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; GENETICS; HEAT; MISSENSE MUTATION; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SUBSTITUTION; CIRCULAR DICHROISM; HOT TEMPERATURE; MODELS, MOLECULAR; MUTATION, MISSENSE; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 77951651339     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.03.023     Document Type: Article

References (39)

1. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
2. Levine A.J., Hu W., Feng Z. The p53 pathway: what questions remain to be explored?. Cell Death Differ. 2006, 13:1027-1036.
3. Bottger V., Bottger A., Garcia-Echeverria C., Ramos Y.F., van der Eb A.J., Jochemsen A.G., Lane D.P. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999, 18:189-199.
4. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
5. Shimizu H., Burch L.R., Smith A.J., Dornan D., Wallace M., Ball K.L., Hupp T.R. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 2002, 277:28446-28458.
6. Wallace M., Worrall E., Pettersson S., Hupp T.R., Ball K.L. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 2006, 23:251-263.
7. Yu G.W., Rudiger S., Veprintsev D., Freund S., Fernandez-Fernandez M.R., Fersht A.R. The central region of HDM2 provides a second binding site for p53. Proc. Natl Acad. Sci. USA 2006, 103:1227-1232.
8. 4 RING, a domain critical for ubiquitination of p53. J. Mol. Biol. 2006, 363:433-450.
9. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 2005, 280:26776-26787.
10. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
11. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 2005, 6:79-87.
12. Kubbutat M.H., Ludwig R.L., Ashcroft M., Vousden K.H. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 1998, 18:5690-5698.
13. Shimizu H., Saliba D., Wallace M., Finlan L., Langridge-Smith P.R., Hupp T.R. Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem. J. 2006, 397:355-367.
14. Burch L., Shimizu H., Smith A., Patterson C., Hupp T.R. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J. Mol. Biol. 2004, 337:129-145.
15. Terzian T., Suh Y.A., Iwakuma T., Post S.M., Neumann M., Lang G.A., et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008, 22:1337-1344.
16. Lukashchuk N., Vousden K.H. Ubiquitination and degradation of mutant p53. Mol. Cell. Biol. 2007, 27:8284-8295.
17. Muller P., Hrstka R., Coomber D., Lane D.P., Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008, 27:3371-3383.
18. Wawrzynow B., Zylicz A., Wallace M., Hupp T., Zylicz M. MDM2 chaperones the p53 tumor suppressor. J. Biol. Chem. 2007, 282:32603-32612.
19. Stevens C., Pettersson S., Wawrzynow B., Wallace M., Ball K., Zylicz A., Hupp T.R. ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1. FEBS J. 2008, 275:4875-4886.
20. Yu G.W., Allen M.D., Andreeva A., Fersht A.R., Bycroft M. Solution structure of the C4 zinc finger domain of HDM2. Protein Sci. 2006, 15:384-389.
21. Lindstrom M.S., Jin A., Deisenroth C., White Wolf G., Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 2007, 27:1056-1068.
22. McCoy M.A., Gesell J.J., Senior M.M., Wyss D.F. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc. Natl Acad. Sci. USA 2003, 100:1645-1648.
23. Worrall E.G., Wawrzynow B., Worrall L., Walkinshaw M., Ball K.L., Hupp T.R. Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J. Chem. Biol. 2009, 2:113-129.
24. Schon O., Friedler A., Freund S., Fersht A.R. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J. Mol. Biol. 2004, 336:197-202.
25. Dastidar S.G., Lane D.P., Verma C.S. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J. Am. Chem. Soc. 2008, 130:13514-13515.
26. Mayo L.D., Turchi J.J., Berberich S.J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 1997, 57:5013-5016.
27. Uhrinova S., Uhrin D., Powers H., Watt K., Zheleva D., Fischer P., et al. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J. Mol. Biol. 2005, 350:587-598.
28. Showalter S.A., Bruschweiler-Li L., Johnson E., Zhang F., Bruschweiler R. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J. Am. Chem. Soc. 2008, 130:6472-6478.
29. Wawrzynow B., Pettersson S., Zylicz A., Bramham J., Worrall E., Hupp T.R., Ball K.L. A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J. Biol. Chem. 2009, 284:11517-11530.
30. Kinoshita E., Kinoshita-Kikuta E., Koike T. Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. Nat. Protoc. 2009, 4:1513-1521.
31. Lo M.C., Aulabaugh A., Jin G., Cowling R., Bard J., Malamas M., Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 2004, 332:153-159.
32. Picksley S.M., Vojtesek B., Sparks A., Lane D.P. Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994, 9:2523-2529.
33. Vojtesek B., Dolezalova H., Lauerova L., Svitakova M., Havlis P., Kovarik J., et al. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 1995, 10:389-393.
34. Chen H.F., Luo R. Binding induced folding in p53-MDM2 complex. J. Am. Chem. Soc. 2007, 129:2930-2937.
35. Neduva V., Russell R.B. DILIMOT: discovery of linear motifs in proteins. Nucleic Acids Res. 2006, 34:W350-W355.
36. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., Lane D.P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 1997, 7:860-869.
37. Candeias M.M., Malbert-Colas L., Powell D.J., Daskalogianni C., Maslon M.M., Naski N., et al. p53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 2008, 10:1098-1105.
38. Fu, X., Yucer, N., Liu, S., Li, M., Yi, P., Mu, J. J. et al. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc. Natl Acad. Sci. USA 107, 4579-4584.
39. Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:275-283.